News and Events
Stay up to date with news and events
Hereditary Disease Foundation (HDF) conference 2022 – Day 4
DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only…
Hereditary Disease Foundation (HDF) conference 2022 – Day 3
Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about…
Hereditary Disease Foundation (HDF) conference 2022 – Day 2
We’re back for day 2 at @hdfcures! This morning’s talks will be focused on clinical trial planning and therapeutic updates from clinical studies. The sheer…
Hereditary Disease Foundation (HDF) conference 2022 – Day 1
Hello and welcome from the HDBuzz team who are currently at the Hereditary Disease Foundation (@hdfcures) 2022 Milton Wexler Biennial Symposium in Boston! It’s the…
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by…